Atezolizumab (Tecentriq®) in combination with bevacizumab.

Assessment Status NCPE assessment ongoing
HTA ID 20060
Drug Atezolizumab in combination with bevacizumab
Brand Tecentriq®
Indication For the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy.  
Assessment Process
Rapid review commissioned 21/12/2020
Rapid review completed 08/02/2021
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab in combination with bevacizumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 24/02/2021
Pre-submission consultation with Applicant 22/11/2021
Full submission received from Applicant 26/07/2022
Preliminary review sent to Applicant 24/11/2022
NCPE assessment re-commenced 22/12/2022
Factual accuracy sent to applicant 08/03/2023
NCPE assessment re-commenced 15/03/2023